GenericsDrug Channels flags a "leaky biosimilar funnel" — development hurdles keep biosimilars from ever reaching marketDrug Channels • Jun 17Fewer biosimilars surviving development means thinner price competition on high-spend biologics, delaying the substitution volume distributors eventually capture in specialty.
GenericsFDA clears Rextovy, a second OTC generic naloxone nasal spray, widening overdose-reversal supplyFDA Press Releases • Jun 16A second OTC 4 mg naloxone adds low-cost generic competition to a high-volume public-health category, modest downward pressure on naloxone pricing.
GenericsRecipharm commits "multi-million-dollar" upgrade to U.S. sterile fill-finish capacityFiercePharma • date unconfirmedMore domestic sterile fill-finish is a slow onshoring signal that could ease chronic injectable-shortage exposure — same theme as Hikma's Ohio build-out last week.
GenericsFDA and UK's MHRA launch liaison program for faster, coordinated regulatory decisionsFiercePharma • date unconfirmedTransatlantic regulatory harmonization could streamline the inspection and approval pathways generics rely on, though near-term ANDA impact is marginal.